Oxford Biomedica PLC Director/PDMR Shareholding (6974N)
20 May 2015 - 4:02PM
UK Regulatory
TIDMOXB
RNS Number : 6974N
Oxford Biomedica PLC
20 May 2015
Oxford BioMedica plc Director's Share Purchase
Oxford, UK - 20 May 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 19 May 2015 one of its
Directors acquired ordinary shares of 1p each ("Ordinary Shares")
as follows:
Interest after
purchase
---------- ----------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
---------- ----------- ---------- ---------------- ------------ --------------
Chief
Financial
Tim Watts Officer 10.3p 194,174 5,802,003 0.23%
---------- ----------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 2,568,145,765 1p
ordinary shares.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy Group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBLGDUCSBBGUC
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024